UTICA, NY -- (Marketwired) -- 07/24/13 -- CONMED Corporation (NASDAQ: CNMD)

• EPS equals $0.34
• Adjusted EPS equals $0.43
• Conference Call to be Held at 10:00 a.m. ET Today

CONMED Corporation (NASDAQ: CNMD) today announced financial results for the second quarter ended June 30, 2013.

"We met our previously forecasted revenues and earnings in the second quarter of 2013 despite a challenging global economy affecting healthcare utilization and hospital capital spending," commented Mr. Joseph J. Corasanti, President and CEO. "Having a broad product portfolio such as ours is extremely beneficial in this environment. It allows us to meet our customers' needs and to take advantage of opportunities as evidenced by the strong showing this quarter in the Surgical Visualization product line."

Second Quarter 2013 Financial Highlights:

• Sales were $193.0 million, an increase of 1.7% (0.1% organic) and 2.3% in constant currency over the second quarter of 2012
  
  
• Diluted earnings per share (GAAP) were $0.34 compared to $0.36 in the second quarter of 2012 (excluding the medical device excise tax or "MDET," EPS would have been $0.37 in 2013)
  
  
• Adjusted diluted earnings per share were $0.43 in the second quarters of both years (excluding the MDET, adjusted EPS would have been $0.46 in 2013)
  
  
• Adjusted EBITDA margin was 16.9%, a decrease of 20 basis points, caused by a 70 basis point negative effect from the MDET offset by operating improvements
  
  

Six Months 2013 Financial Highlights

• Sales were $380.0 million compared to $384.0 million, a decrease of 1.0% (decrease of 2.2% organic) and a decrease of 0.5% in constant currency
  
  
• Diluted earnings per share (GAAP) were $0.71 in both six month periods (excluding the MDET, EPS would have been $0.78 in 2013)
  
  
• Adjusted diluted earnings per share grew to $0.88 compared to $0.85 in the first six months of 2012 (excluding the MDET, EPS would have been $0.94 in 2013)
  
  
• Adjusted EBITDA margin was 17.0%, a decrease of 10 basis points, even with an 80 basis point negative effect from the MDET offset by operating improvements
  
  

International sales in the second quarter of 2013 were $100.0 million, representing 51.8% of total sales. Foreign currency exchange rates including the effects of the FX hedging program caused sales to be $1.1 million less in the second quarter of 2013 compared to sales in the second quarter of 2012.

Cash provided by operating activities increased sequentially from the first quarter 2013 and equaled $17.7 million. For the six months ended June 2013, cash provided by operating activities was $23.2 million. The Company repurchased 582,000 shares of its common stock in the second quarter of 2013 and 1,431,000 shares in the first half of 2013 for $19.0 million and $44.7 million, respectively.

Outlook

"As we look to the rest of 2013, we anticipate continuation of current healthcare trends represented by flat to slightly negative healthcare utilization in the U.S. combined with governmental spending controls in major European countries. While we believe there may be slight moderation of these trends toward the end of 2013, we believe it prudent to tighten our full year 2013 adjusted earnings per share guidance by reducing the top end of the previous guidance range to $1.80 - $1.85 from the former $1.80 - $1.90 per share. This forecast contemplates the effects of the medical device tax and less favorable FX exchange rates," said Mr. Corasanti. "Similarly, we now tighten the forecasted sales range to $770 - $775 million from the prior $770 - $780 million."

"For the third quarter of 2013, we anticipate sales will approximate $184 - $189 million and adjusted earnings per share are forecasted to be $0.37 - $0.42," continued Mr. Corasanti.

The adjusted estimates for the third quarter and full year 2013 exclude special items, such as manufacturing restructuring costs expected to be incurred in 2013 due to the relocation of manufacturing activities from the Westborough, Massachusetts and Tampere, Finland sites to the Company's other facilities and patent litigation.

Special charges

During the second quarter of 2013, the Company continued the on-going consolidation of certain administrative functions and manufacturing activities. Also incurred were litigation costs associated with a patent matter. Expenses associated with these activities, including severance and relocation costs, amounted to $2.4 million, net of tax, in the second quarter of 2013. These charges are included in the GAAP earnings per share set forth above and are excluded from the adjusted results. For the remainder of 2013, the Company presently anticipates incurring additional pre-tax special costs of $6.5 - $7.5 million on projects currently in process.

Use of non-GAAP financial measures

Management has disclosed adjusted financial measurements in this press announcement that present financial information that is not in accordance with generally accepted accounting principles. These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company's on-going financial performance from quarter-to-quarter and year-to-year on a regular basis, and for benchmarking against other medical technology companies. Adjusted net income, adjusted operating income and adjusted earnings per share measure the income of the Company excluding credits or charges that are considered by management to be outside of the normal on-going operations of the Company. Management uses and presents adjusted net income, adjusted operating margin and adjusted earnings per share because management believes that in order to properly understand the Company's short and long-term financial trends, the impact of special items should be eliminated from on-going operating activities. These adjustments for special items are derived from facts and circumstances that vary in frequency and impact on the Company's results of operations. Management uses adjusted net income, adjusted operating income and adjusted earnings per share to forecast and evaluate the operational performance of the Company as well as to compare results of current periods to prior periods on a consistent basis. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company's cash flow. Adjusted financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

Conference call

The Company will webcast its second quarter 2013 conference call live over the Internet at 10:00 a.m. Eastern Time on Wednesday, July 24, 2013. This webcast can be accessed from CONMED's web site at www.conmed.com. Replays of the call will be made available through August 2, 2013.

CONMED profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company's 3,600 employees distribute its products worldwide from several manufacturing locations. CONMED has a direct selling presence in 16 countries outside the United States and international sales constitute approximately 50% of the Company's total sales.

Forward Looking Information

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw material, transportation of litigation; (viii) the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues; and/or (ix) the Company's ability to devise and execute strategies to respond to market conditions.

CONMED CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
(In thousands except per share amounts)
(unaudited)
				Three months ended						Six months ended
				June 30,						June 30,
				2012			2013			2012			2013
Net sales				$	189,695		$	192,993		$	384,011		$	380,007
Cost of sales					88,761			88,471			180,692			171,181
Cost of sales, other - Note A					1,202			1,606			2,676			3,228
Gross profit					99,732			102,916			200,643			205,598
Selling and administrative					73,707			77,174			148,513			154,899
Research and development					7,192			6,591			14,287			12,285
Medical device excise tax					-			1,406			-			2,986
Other expense - Note B					1,775			2,093			3,763			3,906
					82,674			87,264			166,563			174,076
Income from operations					17,058			15,652			34,080			31,522
Loss on early extinguishment of debt					-			-			-			263
Interest expense					1,551			1,383			2,988			2,749
Income before income taxes					15,507			14,269			31,092			28,510
Provision for income taxes					5,211			4,736			10,828			8,485
Net income				$	10,296		$	9,533		$	20,264		$	20,025
Per share data:
	Net income
		Basic		$	.36		$	.35		$	.72		$	.72
		Diluted			.36			.34			.71			.71
	Weighted average common shares
		Basic			28,327			27,591			28,178			27,860
		Diluted			28,672			27,983			28,577			28,258

Note A - Included in cost of sales, other in the three and six months ended June 30, 2012 and 2013 are costs related to the consolidation of our production facilities. Refer to the Reconciliation of Reported Net Income to Adjusted Net Income for further details.

Note B - Other expense in the three and six months ended June 30, 2012 and 2013 includes a number of adjusted charges. Refer to the Reconciliation of Reported Net Income to Adjusted Net Income for further details.

CONMED CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(in thousands)
(unaudited)
ASSETS
				December 31,				June 30,
				2012				2013
Current assets:
	Cash and cash equivalents			$	23,720			$	38,123
	Accounts receivable, net				139,124				140,570
	Inventories				156,228				148,717
	Income taxes receivable				2,897				2,800
	Deferred income taxes				11,931				10,548
	Prepaid expenses and other current assets				14,993				17,848
		Total current assets			348,893				358,606
Property, plant and equipment, net					139,041				137,612
Deferred income taxes					1,057				1,166
Goodwill					249,160				249,160
Other intangible assets, net					190,809				186,823
Other assets					150,547				149,653
		Total assets		$	1,079,507			$	1,083,020
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
	Current portion of long-term debt			$	1,050			$	1,093
	Other current liabilities				124,164				98,062
		Total current liabilities			125,214				99,155
Long-term debt					160,802				233,017
Deferred income taxes					99,857				105,630
Other long-term liabilities					86,636				60,551
		Total liabilities			472,509				498,353
Shareholders' equity:
	Capital accounts				256,672				223,899
	Retained earnings				377,907				389,620
	Accumulated other comprehensive loss				(27,581	)			(28,852	)
		Total equity			606,998				584,667
		Total liabilities and shareholders' equity		$	1,079,507			$	1,083,020

CONMED CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
					Six months ended
					June 30,
					2012				2013
Cash flows from operating activities:
Net income					$	20,264			$	20,025
	Adjustments to reconcile net income to net cash provided by operating activities:
	Depreciation and amortization					23,064				23,816
	Stock-based compensation					2,574				2,496
	Loss on early extinguishment of debt					-				263
	Deferred income taxes					6,091				5,038
		Increase (decrease) in cash flows from changes in assets and liabilities:
			Accounts receivable			(1,027	)			(2,689	)
			Inventories			3,078				(1,581	)
			Accounts payable			1,345				(2,207	)
			Income taxes receivable (payable)			(4,589	)			(1,171	)
			Accrued compensation and benefits			(6,730	)			(7,393	)
			Other assets			(1,779	)			(3,714	)
			Other liabilities			(9,014	)			(9,729	)
	Net cash provided by operating activities					33,277				23,154
Cash flows from investing activities:
			Payments related to distribution agreement			(64,116	)			-
			Purchases of property, plant, and equipment			(11,596	)			(8,201	)
	Net cash used in investing activities					(75,712	)			(8,201	)
Cash flows from financing activities:
			Payments on debt			(32,538	)			(742	)
			Proceeds of debt			57,000				73,000
			Payments related to distribution agreement			-				(34,000	)
			Dividends paid on common stock			(4,328	)			(8,445	)
			Payments related to issuance of debt			-				(1,725	)
			Net proceeds from common stock issued under employee plans			7,868				10,366
			Repurchase of common stock			-				(44,729	)
			Other, net			4,925				7,090
	Net cash provided by financing activities					32,927				815
Effect of exchange rate change on cash and cash equivalents						(294	)			(1,365	)
Net increase (decrease) in cash and cash equivalents						(9,802	)			14,403
Cash and cash equivalents at beginning of period						26,048				23,720
Cash and cash equivalents at end of period					$	16,246			$	38,123

CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO ADJUSTED NET INCOME
Three Months Ended June 30, 2012 and 2013
(In thousands except per share amounts)
(unaudited)
			2012				2013
Reported net income			$	10,296			$	9,533
Facility consolidation costs included in cost of sales				1,202				1,606
Administrative consolidation costs included in other expense				1,231				1,566
Legal arbitration and patent dispute costs included in other expense				544				527
	Total other expense			1,775				2,093
Adjusted expense before income taxes				2,977				3,699
Provision (benefit) for income taxes on adjusted expenses				(1,072	)			(1,332	)
Adjusted net income			$	12,201			$	11,900
Per share data:
Reported net income
	Basic		$	0.36			$	0.35
	Diluted			0.36				0.34
Adjusted net income
	Basic		$	0.43			$	0.43
	Diluted			0.43				0.43

Management has provided the above reconciliation of net income to adjusted net income as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section "Use of Non-GAAP Financial Measures" above.

CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO ADJUSTED NET INCOME
Six Months Ended June 30, 2012 and 2013
(In thousands except per share amounts)
(unaudited)
		2012				2013
Reported net income		$	20,264			$	20,025
Facility consolidation costs included in cost of sales			2,676				3,228
Administrative consolidation costs included in other expense			1,504				3,170
Costs associated with purchase of Nordic region distributor			704				-
Legal arbitration and patent dispute costs included in other expense			1,555				736
	Total other expense		3,763				3,906
Loss on early extinguishment of debt			-				263
Adjusted expense before income taxes			6,439				7,397
Provision (benefit) for income taxes on adjusted expenses			(2,318	)			(2,663	)
Adjusted net income		$	24,385			$	24,759
Per share data:
Reported net income
	Basic	$	0.72			$	0.72
	Diluted		0.71				0.71
Adjusted net income
	Basic	$	0.87			$	0.89
	Diluted		0.85				0.88

Management has provided the above reconciliation of net income to adjusted net income as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section "Use of Non-GAAP Financial Measures" above.

CONMED CORPORATION
RECONCILIATION OF INCOME FROM OPERATIONS TO ADJUSTED INCOME FROM OPERATIONS
(In thousands)
(unaudited)
			Three months ended								Six months ended
			June 30,								June 30,
			2012				2013				2012				2013
Reported income from operations			$	17,058			$	15,652			$	34,080			$	31,522
Facility consolidation costs included in cost of sales				1,202				1,606				2,676				3,228
Administrative consolidation costs included in other expense				1,231				1,566				1,504				3,170
Medical device excise tax				-				1,406				-				2,986
Costs associated with purchase of Nordic region distributor				-				-				704				-
Legal arbitration and patent dispute costs included in other expense				544				527				1,555				736
Adjusted income from operations			$	20,035			$	20,757			$	40,519			$	41,642
Operating Margin
	Reported			9.0	%			8.1	%			8.9	%			8.3	%
	Adjusted			10.6	%			10.8	%			10.6	%			11.0	%

Management has provided the above reconciliation as an additional measure that investors can use to compare financial results between reporting periods. Management believes this reconciliation provides a useful presentation of financial measures as discussed in the section "Use of Non-GAAP Financial Measures" above.

CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO EBITDA & ADJUSTED EBITDA
(in thousands)
(unaudited)
		Three months ended								Six months ended
		June 30,								June 30,
		2012				2013				2012				2013
Net income		$	10,296			$	9,533			$	20,264			$	20,025
Provision for income taxes			5,211				4,736				10,828				8,485
Interest expense			1,551				1,383				2,988				2,749
Loss on early extinguishment of debt			-				-				-				263
Depreciation			4,586				4,549				9,274				9,168
Amortization			6,459				7,389				13,423				14,381
EBITDA		$	28,103			$	27,590			$	56,777			$	55,071
Stock-based compensation			1,391				1,344				2,574				2,496
Facility consolidation costs included in cost of sales			1,202				1,606				2,676				3,228
Administrative consolidation costs included in other expense			1,231				1,566				1,504				3,170
Costs associated with purchase of Nordic region distributor			-				-				704				-
Legal arbitration and patent dispute costs included in other expense			544				527				1,555				736
Adjusted EBITDA		$	32,471			$	32,633			$	65,790			$	64,701
EBITDA Margin
	EBITDA		14.8	%			14.3	%			14.8	%			14.5	%
	Adjusted EBITDA		17.1	%			16.9	%			17.1	%			17.0	%

Management has provided the above reconciliations as additional measures that investors can use to compare financial results between reporting periods. Management believes these reconciliations provide a useful presentation of financial measures as discussed in the section "Use of Non-GAAP Financial Measures" above.

CONMED CORPORATION
Second Quarter Sales Summary
(in millions)
		Three Months Ended June 30,
											Constant
											Currency
		2012			2013			Growth			Growth
Orthopedic surgery		$	103.8		$	101.8		-1.9	%		-1.1	%
General surgery			71.6			73.2		2.2	%		2.7	%
Surgical visualization			14.3			18.0		25.9	%		25.2	%
		$	189.7		$	193.0		1.7	%		2.3	%
Single-use products		$	153.6		$	153.8		0.1	%		0.7	%
Capital products			36.1			39.2		8.6	%		9.2	%
		$	189.7		$	193.0		1.7	%		2.3	%

CONMED CORPORATION
Six Months Sales Summary
(in millions)
		Six Months Ended June 30,
											Constant
											Currency
		2012			2013			Growth			Growth
Orthopedic surgery		$	210.7		$	206.9		-1.8	%		-1.2	%
General surgery			141.0			140.0		-0.7	%		-0.4	%
Surgical visualization			32.3			33.1		2.5	%		3.1	%
		$	384.0		$	380.0		-1.0	%		-0.5	%
Single-use products		$	307.2		$	301.6		-1.8	%		-1.3	%
Capital products			76.8			78.4		2.1	%		2.6	%
		$	384.0		$	380.0		-1.0	%		-0.5	%

CONTACT:
CONMED Corporation
Robert Shallish
Chief Financial Officer
315-624-3206

Source: CONMED Corporation